Cited 0 times in
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최준용 | - |
dc.date.accessioned | 2017-10-26T08:09:58Z | - |
dc.date.available | 2017-10-26T08:09:58Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 2093-2340 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/153054 | - |
dc.description.abstract | The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) were analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-na?ve and ART-experienced Asian subjects infected with human immunodeficiency virus (HIV)-1. Studies GS-US-236-102 and GS-US-236-103 were randomized, double-blind, placebo-controlled, 144-week studies conducted in ART-na?ve subjects, comparing E/C/F/TDF versus efavirenz (EFV)/F/TDF or ritonavir-boosted atazanavir (ATV+RTV) plus emtricitabine/tenofovir DF (F/TDF), respectively. Studies GS-US-236-115 and GS-US-236-121 were randomized, open-label, 96-week long conducted in ART-experienced subjects, who switched to E/C/F/TDF from ritonavir-boosted protease inhibitors (PI+RTV)+F/TDF, or non-nucleoside reverse transcriptase inhibitors (NNRTI)+F/TDF regimens. The E/C/F/TDF appeared to have sustained efficacy and safety and was well tolerated in the small number of ART-na?ve and ART-experienced Asian subjects. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean, English | - |
dc.publisher | 대한감염학회 | - |
dc.relation.isPartOf | INFECTION AND CHEMOTHERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials | - |
dc.type | Article | - |
dc.publisher.location | Korea | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Jun Yong Choi | - |
dc.contributor.googleauthor | Somnuek Sungkanuparph | - |
dc.contributor.googleauthor | Thanomsak Anekthananon | - |
dc.contributor.googleauthor | Paul Sax | - |
dc.contributor.googleauthor | Edwin DeJesus | - |
dc.contributor.googleauthor | Howard Edelstein | - |
dc.contributor.googleauthor | Mark Nelson | - |
dc.contributor.googleauthor | Jennifer DeMorin | - |
dc.contributor.googleauthor | Hui C. Liu | - |
dc.contributor.googleauthor | Raji Swamy | - |
dc.contributor.googleauthor | Joonwoo Bahn | - |
dc.contributor.googleauthor | SunJin Hwang | - |
dc.contributor.googleauthor | Sang Youn Yang | - |
dc.contributor.googleauthor | Christopher Ng | - |
dc.contributor.googleauthor | David Piontkowsky | - |
dc.identifier.doi | 10.3947/ic.2015.48.3.219 | - |
dc.contributor.localId | A04191 | - |
dc.relation.journalcode | J01053 | - |
dc.identifier.eissn | 2092-6448 | - |
dc.relation.journalsince | 2011~ | - |
dc.identifier.pmid | 27704731 | - |
dc.relation.journalbefore | ~2010 감염과 화학요법 | - |
dc.subject.keyword | Antiretroviral therapy | - |
dc.subject.keyword | Asian Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate | - |
dc.subject.keyword | Human immunodeficiency virus | - |
dc.contributor.alternativeName | Choi, Jun Yong | - |
dc.contributor.affiliatedAuthor | Choi, Jun Yong | - |
dc.citation.volume | 48 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 219 | - |
dc.citation.endPage | 224 | - |
dc.identifier.bibliographicCitation | INFECTION AND CHEMOTHERAPY, Vol.48(3) : 219-224, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 41058 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.